Atmo Biosciences exhibited at Australian Gastroenterology Week Conference in Adelaide thanks to the generous support of C.R. Kennedy. CEO Mal Hebblewhite reported plenty of interest from gastroenterologists regarding the two clinical trials Atmo recently commenced with Professor Peter Gibson at Monash University. There was also lots of discussion about using the Atmo Gas Capsule as a research tool and potential applications in motility, bacterial overgrowth, IBS, and IBD....

Read More

Atmo Biosciences has signed a licensing deal with RMIT University securing the exclusive worldwide rights to commercialize a ground-breaking ingestible gas-sensing capsule. The Atmo Gas Capsule is set to revolutionize how doctors diagnose and treat common gastrointestinal (GI) disorders by offering a non-invasive, low-cost, and more accurate alternative to current technologies. Patients with gut problems will be able to swallow the capsule – about the size of a vitamin pill – and get real time, continuous detection and measurement of hydrogen, methane, and oxygen in the gut. The data can be sent via a handheld receiver and mobile app to the cloud,...

Read More

Findings from the first human trials of a breakthrough gas-sensing swallowable capsule could revolutionise the way that gut disorders and diseases are prevented and diagnosed. The trials by researchers at RMIT University have uncovered mechanisms in the human body that have never been seen before, including a potentially new immune system. The new technology and discoveries offer a game-changer for the one-in-five people worldwide who will suffer from a gastrointestinal disorder in their lifetime. They could also lead to fewer invasive procedures like colonoscopies. The ingestible capsule (the size of a vitamin pill) detects and measures gut gases – hydrogen, carbon dioxides and...

Read More